부산대학교 도서관

Abstract. Iodine-131 labelled anti L1-CAM antibody mAb chCE7 was compared with the effective neuroblastoma-seeking agent [sup 131]I-labelled metaiodobenzylguanidine (MIBG) with regard to (a) its therapeutic efficacy in treating nude mice with neuroblastoma xenografts and (b) its tumour targetting ability in neuroblastoma patients. The SK-N-SH tumour cells used in the mouse experiments show good MIBG uptake and provide a relatively low number of 6,300 binding sites/cell for mAb chCE7. Tumours were treated with single injections of [sup 131]I-MIBG (110 MBq) and with [sup 131]I-labelled mAb chCE7 (17 MBq) and both agents showed antitumour activity. After therapy with [sup 131]I-chCE7, the subcutaneous tumours nearly disappeared; treatment with [sup 131]I-MIBG was somewhat less effective, resulting in a 70% reduction in tumour volume. A calculated tumour regrowth delay of 9 days occurred with a radioactivity dose of 17 MBq of an irrelevant control antibody mAb 35, which does not bind to SK-N-SH cells, compared with a regrowth delay of 34 days with [sup 131]I-mAb chCE7 and of 24 days with [sup 131]I-MIBG. General toxicity appeared to be mild, as assessed by a... [ABSTRACT FROM AUTHOR]